Leadership changeCompany-reported
What was reported
SAN DIEGO - (BUSINESS WIRE- September 10, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 10, 2026 · Open the source ↗
What the evidence supports
Dexcom told the SEC (Form 8-K, Item 5.02) that there was a change involving its directors or officers, or their pay arrangements. The filing gives Sep 10, 2026 as the date of the earliest event reported. The company also furnished a press release, which is its own account rather than a regulatory statement.
What remains unknown
The reasons for the change beyond those stated, and what it means for the company's strategy or results.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineDexcom Appoints Glenn Boehnlein to Board of DirectorsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 10, 2026 · Open the source ↗
Press release lead paragraphSAN DIEGO - (BUSINESS WIRE- September 10, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 8-K · Sep 10, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
Dexcom Appoints Glenn Boehnlein to Board of Directors
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.